Kostas N. Botsoglou, MD

Targeting Disease Modification for Psoriasis and Psoriatic Arthritis

17:30 - Defining Minimal Disease Activity

35:35 - Preventing Progression from PSO to PSA

Videos

Medical experts engage in a discussion surrounding the treatment and management of patients diagnosed with psoriasis and psoriatic arthritis.

0:00 Overlap of PsO and PsA
4:00 Detecting Early PsA
13:20 Treatments for PsA
18:00 Defining Minimal Disease Activity
24:50 Biologics for PsA
31:00 Efficacy of IL-17i and IL-23i
37:00 Preventing Progression from PsO to PsA

Dermatologic experts explore strategies to slow the progression of psoriasis to psoriatic arthritis, offering evidence-based insights to optimize patient outcomes and enhance long-term disease management.

Targeting Disease Modification in Psoriasis and Psoriatic Arthritis

Expert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers.

Resources for Patients and Providers on Adalimumab Biosimilars

This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD.

The conversation delves into various educational resources utilized both by healthcare providers and patients regarding ddalimumab biosimilars. Providers emphasize the importance of authoritative sources such as the FDA and professional societies like the American College of Rheumatology for accurate information on interchangeability and biosimilars.

While some providers note a lack of comprehensive resources, they highlight the American Academy of Dermatology and New Zealand DermNet as useful references. Patient education materials from organizations like the Crohn's and Colitis Foundation are also recommended.

Providers stress the need for proactive patient engagement and filtering information from reliable sources, discouraging reliance on social media or blogs for medical advice. To ensure patient understanding, nurses play a crucial role in creating educational tools and facilitating communication, including preemptive notifications about changes in medication availability.

Overall, the discussion underscores the importance of ongoing education and communication between healthcare providers and patients to optimize treatment outcomes with Adalimumab biosimilars.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.

Providers in inflammatory diseases discuss the instrumental role nurses and support staff play in educating patients on adalimumab biosimilars.

The Role of Nurses and Support Personal in Educating Patient on Adalimumab Biosimilars

The conversation centers on the crucial role of nurses and support staff in educating patients and ensuring optimal outcomes with adalimumab biosimilars. Nurses are highlighted as key educators who interact closely with patients, providing training on device usage and addressing any issues that arise. Support staff, including specialty pharmacists and biologics coordinators, also play essential roles in managing patient concerns, such as delays in medication delivery or copay assistance.

Providers emphasize the importance of patient education from the outset, including information on risks, side effects, and access to copay assistance programs. Proactive patient engagement is encouraged, with patients urged to communicate any issues promptly to facilitate timely resolution.

Collaboration between healthcare providers, pharmaceutical companies, and support staff is crucial in navigating the complexities of insurance coverage and product availability. Open communication and ongoing education ensure that patients receive comprehensive support throughout their treatment journey, despite potential changes in coverage and policies over time.

Kostas N. Botsoglou, MD

Articles